Radiation sensitizers.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001972:Bromodeoxycytidine / Q000009:adverse effects / Q000494:pharmacology; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002277:Carcinoma / Q000098:blood supply / Q000532:radiotherapy; D003857:Deoxyuridine / Q000031:analogs & derivatives / Q000494:pharmacology; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D005467:Floxuridine / Q000494:pharmacology; D006801:Humans; D000860:Hypoxia; D007065:Idoxuridine / Q000494:pharmacology; D008175:Lung Neoplasms / Q000628:therapy; D008727:Methotrexate / Q000494:pharmacology; D008795:Metronidazole / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000494:pharmacology; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D012106:Research; D012513:Sarcoma, Experimental / Q000532:radiotherapy; D012867:Skin / Q000187:drug effects
D000970:Antineoplastic Agents; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D005467:Floxuridine; D001972:Bromodeoxycytidine; D008795:Metronidazole; D001973:Bromodeoxyuridine; D007065:Idoxuridine; D003857:Deoxyuridine; D008727:Methotrexate